Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 649-658

  Oosterhoff, Dinja ^a   Lougheed, Sinéad M ^a   van de Ven, Rieneke ^a   Lindenberg, Jelle J ^a   van Cruijsen, Hester ^a   Hiddingh, Lotte ^a   Kroon, Jan ^a   van den Eertwegh, Alfons J M ^a   Hangalapura, Basav N ^a   Scheper, Rik J ^a   de Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cell; Differentiation; IL 6; Microenvironment; P38 MAPK; STAT3; Suppression; Tumor

Indexed keywords

CD14 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; T6 ANTIGEN;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL SUSPENSION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME INHIBITION; GLIOMA; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; SUPERNATANT; T LYMPHOCYTE; TH1 CELL; TUMOR MICROENVIRONMENT;

EID: 84882246825     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20365     Document Type: Article

References (47)

1. Steinman RM. Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med 2007; 13:1155-9; PMID:17917664; http://dx.doi.org/10.1038/nm1643.
2. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012; PMID:22313874; http://dx.doi. org/10.1016/j.semcancer.2012.01.011.
3. Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, de Gruijl TD. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy 2011; 3:77-96; PMID:21174559; http://dx.doi.org/10.2217/ imt.10.95.
4. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, et al. IL-6 is required for glioma development in a mouse model. Oncogene 2004; 23:3308-16; PMID:15064729; http://dx.doi. org/10.1038/sj.onc.1207455.
5. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474-88; PMID:10851046; http://dx.doi.org/10.1038/ sj.onc.1203527.
6. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21:2000-8; PMID:11960372; http://dx.doi. org/10.1038/sj.onc.1205260.
7. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51; PMID:17186030; http://dx.doi.org/10.1038/nri1995.
8. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http:// dx.doi.org/10.1038/nrc2734.
9. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005; 175:4338-46; PMID:16177074.
10. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54; PMID:14702634; http:// dx.doi.org/10.1038/nm976.
11. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506-13; PMID:19244102; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323.
12. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67:9630-6; PMID:17942891; http://dx.doi.org/10.1158/0008-5472.CAN-07-1243.
13. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation and cancer: how intimate is the relationship? Ann NY Acad Sci 2009; 1171:59-76; PMID:19723038; http:// dx.doi.org/10.1111/j.1749-6632.2009.04911.x.
14. Xie J, Qian J, Yang J, Wang S, Freeman ME, 3rd, Yi Q. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol 2005; 33:564-72; PMID:15850834; http://dx.doi.org/10.1016/j. exphem.2005.03.001.
15. Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006; 107:2432-9; PMID:16291589; http://dx.doi.org/10.1182/blood- 2005-06-2486.
16. Wang S, Hong S, Yang J, Qian J, Zhang X, Shpall E, et al. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006; 108:4071-7; PMID:16917008; http://dx.doi.org/10.1182/blood-2006-04-016980.
17. Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009; 15:4382-90; PMID:19549770; http://dx.doi.org/10.1158/1078-0432.CCR-09-0399.
18. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002; 168:4333-43; PMID:11970975.
19. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150-66; PMID:9834220.
20. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507-13; PMID:17483367; http://dx.doi. org/10.1158/0008-5472.CAN-06-4174.
21. Hegde S, Pahne J, Smola-Hess S. Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NFkappaB binding activity and CCR7 expression. FASEB J 2004; 18:1439-41; PMID:15247147.
22. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, et al. TGF-beta1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999; 162:4567-75; PMID:10201996.
23. Park SJ, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173:3844-54; PMID:15356132.
24. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18:849-61; PMID:12818165; http://dx.doi. org/10.1016/S1074-7613(03)00152-3.
25. Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007; 67:5479-88; PMID:17545630; http://dx.doi. org/10.1158/0008-5472.CAN-06-3963.
26. van Cruijsen H, Oosterhoff D, Lindenberg JJ, Lougheed SM, Fehres C, Weijers K, et al. Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. Immunotherapy 2011; 3:1051-61; PMID:21913828; http://dx.doi. org/10.2217/imt.11.107.
27. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007; 86:800-11; PMID:17720847; http://dx.doi. org/10.1177/154405910708600902.
28. Mögel I, Baumann S, Böhme A, Kohajda T, von Bergen M, Simon JC, et al. The aromatic volatile organic compounds toluene, benzene and styrene induce COX-2 and prostaglandins in human lung epithelial cells via oxidative stress and p38 MAPK activation. Toxicology 2011; 289:28-37; PMID:21801798; http://dx.doi.org/10.1016/j.tox.2011.07.006.
29. Yang WS, Park YC, Kim JH, Kim HR, Yu T, Byeon SE, et al. Nanostructured, self-assembling peptide K5 blocks TNFa and PGE2 production by suppression of the AP-1/p38 pathway. Mediators Inflamm 2012; Epub ahead of press; PMID:22315508; http://dx.doi.org/10.1155/2012/489810.
30. Feng YJ, Li YY. The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease. J Dig Dis 2011; 12:327-32; PMID:21955425; http://dx.doi.org/10.1111/j.1751-2980.2011.00525.x.
31. Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, et al. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 2011; 71:5467-76; PMID:21730023; http://dx.doi.org/10.1158/0008-5472.CAN-10-3988.
32. + T cells. J Exp Med 2012; 209:109-21; PMID:22213806; http://dx.doi.org/10.1084/ jem.20110399.
33. Xie J, Qian J, Wang S, Freeman ME, 3rd, Epstein J, Yi Q. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J Immunol 2003; 171:4792-800; PMID:14568957.
34. Harizi H, Limem I, Gualde N. CD40 engagement on dendritic cells induces cyclooxygenase-2 and EP2 receptor via p38 and ERK MAPKs. Immunol Cell Biol 2011; 89:275-82; PMID:20697426; http://dx.doi.org/10.1038/icb.2010.94.
35. Yang Z, Zhang X, Darrah PA, Mosser DM. The regulation of Th1 responses by the p38 MAPK. J Immunol 2010; 185:6205-13; PMID:20937847; http://dx.doi. org/10.4049/jimmunol.1000243.
36. Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005; 5:929-39; PMID:16178738; http:// dx.doi.org/10.2174/1568026054985911.
37. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 2011; 17:5850-7; PMID:21673068; http://dx.doi.org/10.1158/1078-0432.CCR-10-2574.
38. Escors D, Lopes L, Lin R, Hiscott J, Akira S, Davis RJ, et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008; 111:3050-61; PMID:18180378; http://dx.doi.org/10.1182/blood- 2007-11-122408.
39. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 downregulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004; 165:1853-63; PMID:15579430; http://dx.doi.org/10.1016/S0002-9440(10)63238-5.
40. Wu L, Du H, Li Y, Qu P, Yan C. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol 2011; 179:2131-41; PMID:21864492; http://dx.doi.org/10.1016/j.ajpath.2011.06.028.
41. Lu J, Zhao J, Liu K, Zhao J, Yang H, Huang Y, et al. MAPK/ERK1/2 signaling mediates endothelial-like differentiation of immature DCs in the microenvironment of esophageal squamous cell carcinoma. Cell Mol Life Sci 2010; 67:2091-106; PMID:20221785; http:// dx.doi.org/10.1007/s00018-010-0316-8.
42. Adler HS, Steinbrink K. MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle 2008; 7:169-70; PMID:18212528; http://dx.doi.org/10.4161/ cc.7.2.5312.
43. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196:121-35; PMID:8841451; http://dx.doi.org/10.1016/0022-1759(96)00079-8.
44. van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, Hooijberg JH, et al. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol 2006; 176:5191-8; PMID:16621983.
45. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62:5736-42; PMID:12384532.
46. Baars A, Claessen AM, van den Eertwegh AJ, Gall HE, Stam AG, Meijer S, et al. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol 2000; 11:965-70; PMID:11038032; http://dx.doi. org/10.1023/A:1008363601515.
47. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353:345-50; PMID:9950438; http://dx.doi.org/10.1016/S0140-6736(98)07186-4.